Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois.

"[3][dead link‍] Hospira became an independent company on May 3, 2004, with 14,000 employees, 14 manufacturing sites and an estimated $2.5 billion in annual sales.

[6] In 2007, Hospira purchased Mayne Pharma Ltd., an Australian-based specialty injectable pharmaceuticals company, for $2.1 billion.

[9] In 2010, Hospira acquired Javelin Pharmaceuticals, Inc., maker of post-operative pain management drug Dyloject, for approximately $145 million.

[15][16][17] In 2020 through 2022, Pfizer used Hospira, Inc. as a trade name in reference to the subsidiary's involvement in as a supplier of 0.9% Sodium chloride Injection USP diluent for use with the Pfizer–BioNTech COVID-19 vaccine.

[24] Company officials determined there was no way it could prevent sodium thiopental from being used in executions, and did not want to expose their employees to liability.

[25][24][26] In August 2009, Hospira introduced a generic version of oxaliplatin, originally developed by Sanofi-Aventis SA for treating colon cancer.

[29] In 2014-2015 two security researchers independently identified what were described as severe defects in Hospira's PCA system firmware, the software controlling various of their drug infusion equipment (CVE-2015-3459[30] and further advisory ICSA-15-125-01B[31]).

Numerous remote exploit vulnerabilities were found, in what was believed to be the first FDA safety advisory of its kind.